Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies.

  title={Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies.},
  author={George I. Papakostas and Stephen M Stahl and Alok Krishen and Cheryl A Seifert and Vivian L. Tucker and Elizabeth P. Goodale and Maurizio Fava},
  journal={The Journal of clinical psychiatry},
  volume={69 8},
OBJECTIVE The goal of this work was to compare the efficacy of the norepinephrine and dopamine reuptake inhibitor bupropion with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depressive disorder with high levels of anxiety (anxious depression). METHOD Ten double-blind, randomized studies from 1991 through 2006 were combined (N = 2122). Anxious depression was defined as a 17-item Hamilton Rating Scale for Depression (HAM-D-17) anxiety-somatization factor score… 

Figures and Tables from this paper

Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan
Vortioxetine may be effective for patients with anxiety symptoms in MDD and further research is warranted to investigate these effects in a real-world clinical setting.
The Role of Bupropion in the Management of Major Depressive Disorder
Bupropion has been used in the treatment of geriatric depression with good therapeutic efficacy and health outcome measurements and has also shown usefulness as a smoking cessation agent and in treating depression in patients with medical co-morbidities such as asthma and HIV.
Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline
  • B. Bandelow, M. Bauer, H. Eriksson
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2014
Adjunct quetiapine XR demonstrates efficacy in patients with anxious and non-anxious depression, assessed usingHAM-A total score, and anxious depression assessed using HAM-D anxiety/somatisation factor score.
Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
The efficacy of venlafaxine extended release for major depressive disorder treatment in patients with anxiety symptoms is supported, and changes from baseline to final visit in Montgomery–Åsberg Depression Rating Scale total score and response and remission rates were analyzed.
Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effective with regard to improvement from baseline in assessments of anxiety and functional impairment, and numerous other clinical endpoints.
[Psychopharmacology of anxiety and depression: Historical aspects, current treatments and perspectives].
  • H. Javelot
  • Psychology
    Annales pharmaceutiques francaises
  • 2016
Agomelatine: efficacy at each phase of antidepressant treatment.
The antidepressant efficacy of agomelatine is maintained over the long term; almost 80% of patients remain free from relapse after 10 months of treatment.
Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study
Anxious depression status was not found to predict symptom improvement, or serve as a moderator of clinical improvement to cotherapy versus monotherapy, but the advantage in remission rates in favor of cotherapy vs monotherapy was, numerically, much larger for patients with anxious depression than it was for patients without anxious MDD.


Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
Nefazodone was found to have an excellent safety profile and was well tolerated, with 5% of nefazodones patients prematurely discontinuing treatment for adverse experiences compared with 17% for imipramine and 5% for placebo treatment.
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
Because of its favorable side effect profile, bupropion SR may provide a safe and effective nonserotonergic treatment alternative that is well suited as an antidepressant for the elderly.
Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.
The principal difference between these treatments was that sexual dysfunction commonly complicated SSRI therapy, whereas treatment with bupropion caused no more sexual dysfunction than placebo.
Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
Anxiety in major depression does not appear to affect response to an antidepressant, and antidepressant selection should be determined by an agent's overall risk:benefit ratio, not the presence or absence of anxiety.
Does pretreatment anxiety predict response to either bupropion SR or sertraline?
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant, suggesting any one of the medications in the study provided a reasonable second-step choice for patients with depression.
Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline
A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice
It is indicated that sertraline is an effective agent to use in primary care patients with depression and associated symptoms of anxiety and is better tolerated than the tricyclic comparator clomipramine.